We have recently shown that the pan-Bcl-2 inhibitor obatoclax induces cell cycle arrest and blocks migration in CRC cells rather than causing direct cell death, arguing for pleiotropic antitumor effects of this agent [21]. Here, BCL2 is linked to colorectal carcinoma.